


The Changing Face of MRSA: Evolving Epidemiology

Dr. Andrew Simor, University of Toronto

A Webber Training Teleclass

The Changing Face of MRSA: Evolving Epidemiology



Andrew E. Simor, MD, FRCPC, FACP
Sunnybrook Health Sciences Centre
University of Toronto

Hosted by Paul Webber
paul@webbertraining.com

www.webbertraining.com

Disclosures

I have received grants, and served as a consultant on Advisory Boards for:

- Astellas Pharma
- BD GeneOhm
- Janssen-Ortho
- Pfizer Canada
- Sepracor Pharmaceuticals
- Wyeth Pharmaceuticals


Objectives

- to appreciate the changing epidemiology of healthcare-associated and community-associated MRSA
- to consider evidence-based infection prevention and control strategies

Staphylococcus aureus

- *S. aureus* is most common cause of healthcare-associated infections
- MRSA is the major antibiotic-resistant organism in hospitals; CA-MRSA increasing

Global Prevalence of MRSA, 2006



Grundmann, Lancet 2006

Prevalence of MRSA in US Healthcare Facilities

- point-prevalence survey, 1,237 hospitals and nursing homes, Oct. 2006 (21% of all US facilities)
- 46/1,000 inpatients infected/colonized with MRSA;
- 34/1,000 inpatients infected
- underestimate; little active screening




Jarvis, Am J Infect Control 2007

Hosted by Paul Webber paul@webbertraining.com

www.webbertraining.com

The Changing Face of MRSA: Evolving Epidemiology

Dr. Andrew Simor, University of Toronto
A Webber Training Teleclass



MRSA Bloodstream Infections

Location	MRSA as a % of <i>S. aureus</i> bacteremias
U.K.*	36
Ontario†	19
Quebec‡	24

* Jeyarajam, BMJ 2008; † QMPLS, 2008; ‡ Institut National de Santé Publique du Québec, 2008

MRSA in Canada

Last year, there were:
 approx 21,000 new MRSA patients
 6,700 new MRSA infections
 1,300 MRSA-related deaths
 \$200-250 million excess costs attributable to MRSA

MRSA Impact

- attributable mortality and morbidity (Whitby, Med J Austr 2001; Cosgrove, Clin Infect Dis 2003)
- prolonged hospital length of stay (Engemann, Clin Infect Dis 2003; Cosgrove, Infect Control Hosp Epidemiol 2005)
- excess/attributable costs, \$14,360 (Kim, Infect Control Hosp Epidemiol 2001)

The Changing Face of MRSA: Evolving Epidemiology

Dr. Andrew Simor, University of Toronto
A Webber Training Teleclass

Mortality Associated with *S. aureus* Bacteremia – A Meta-Analysis




Figure 1. Forest plot summary of the unadjusted results of the 31 studies included in the meta-analysis. The OR and 95% CI are shown for each study. The pooled OR is 1.53 (95% CI: 1.16-2.02). There was significant heterogeneity among the studies' results ($I^2 = 93$).

Cosgrove, Clin Infect Dis 2003

MRSA Surgical Site Infections

Outcome	Uninfected (N=193)	MSSA (N=165)	MRSA (N=121)	p value
Death (%)	2.1	6.7	20.7	<0.001
Hospital (days)	5	14	23	<0.001
Median cost (\$)	29,455	52,791	92,363	<0.001


Engemann, Clin Infect Dis 2003

Why does antibiotic resistance affect outcome?

- Host factors
- Organism virulence
- Delay in instituting effective therapy (or vancomycin less effective)

Bradley, Clin Infect Dis 2002; Paterson, Clin Infect Dis 2004; Kim, Antimicrob Agents Chemother 2008

Community-associated MRSA



Community-associated MRSA from laboratory-based surveillance, San Francisco, CA, Miller, Clin Infect Dis 2008.

MRSA in Emergency Dept. Skin/Soft Tissue Infections

- surveillance in 11 urban hospitals, August 2004
- 15-74% infections MRSA (mean 59%); single most common pathogen
- 97% of these were CA-MRSA (USA 300; SCC_{mec} IV; PVL+)

Moran, NEJM 2006

MRSA in Emergency Departments Toronto, March – June 2007

- SSTI surveillance; 298 with *S. aureus*
- 18% of *S. aureus* were MRSA
- 52% of MRSA were CMRSA-10 (USA300)

Adam, AMMI/CACMID 2008; Abstr. SP-31

The Changing Face of MRSA: Evolving Epidemiology

Dr. Andrew Simor, University of Toronto
A Webber Training Teleclass

MRSA in Canada Acquisition

Acquisition	1995-2002	2003-2007
Healthcare-associated	92.8	79.5
Community-associated	7.2	20.5


Canadian Nosocomial Infection Surveillance Program

Community-Associated MRSA

Clonal predominance

- CMRSA10 (USA300)
- CMRSA7 (USA400)

Dissemination of CA-MRSA




Wylie, J Clin Microbiol 2005; Mulvey, Emerg Infect Dis 2005; Gilbert CMAJ 2006.

CA-MRSA Patient Profile

- often younger
- IVDU, MSM
- incarcerated, homeless
- sports teams
- native aboriginals

Groom, JAMA 2001; Pan, CID 2003; Naimi, JAMA 2003; Begier, CID 2004; Kazakov, NEJM 2005



Kazakova, NEJM 2005

CA-MRSA

Clinical Presentations





- skin/soft tissue, furuncles, abscess, cellulitis, necrotizing fasciitis
- necrotizing pneumonia ± empyema
- bone/joint infection
- toxic-shock syndrome

Hosted by Paul Webber paul@webbertraining.com
www.webbertraining.com

The Changing Face of MRSA: Evolving Epidemiology

Dr. Andrew Simor, University of Toronto

A Webber Training Teleclass



Emergence of CA-MRSA as a Cause of Healthcare-Associated Infections

- USA400 post-partum infections, NY mastitis, cellulitis, abscesses (Saiman, CID 2003)
- USA300 prosthetic joint infections, Atlanta, GA (Kourbatova, Am J Infect Control 2005)
- USA300 accounted for 28% healthcare-associated bacteremias, 20% nosocomial MRSA BSIs, Atlanta, GA (Seybold, CID 2006)
- USA300 common cause of SSI, University of Alabama (Patel, J Clin Microbiol 2007)

Hosted by Paul Webber paul@webbertraining.com
www.webbertraining.com

The Changing Face of MRSA: Evolving Epidemiology

Dr. Andrew Simor, University of Toronto

A Webber Training Teleclass

CA-MRSA Virulence

- USA 300/400 more virulent than other strains of *S. aureus*/MRSA in a mouse model of bacteremia
- more resistant to killing by human PMNs

Voyich, J Immunol 2005

INFECTIOUS DISEASE » 'WHEN I CAME HOME, I STARTED TO HAVE BAD PAIN'

Hospital sued over crippling superbug

Seeking \$350,000, man says poor controls left him vulnerable

BY LISA PRIEST TORONTO

A young man training to become a chef is suing a Toronto hospital, claiming inadequate isolation and infection-control procedures caused him to catch a superbug, permanently disabling him.

Matthew Rash, 30, said he tested negative for methicillin-resistant *Staphylococcus aureus* (MRSA) when he was admitted to Bridgepoint Hospital almost four years ago. He was sent there for rehabilitation after

undergoing surgery at another hospital for injuries, including a broken left leg, fractured right foot and ankle, which were the result of a car crash.

"When I came home [from Bridgepoint], I started to have bad pain," Mr. Rash said in a telephone interview. "I went to the doctor; she took off my bandage and green goo floated out of my foot."

He is seeking \$350,000 in damages, saying Bridgepoint did not move an alleged MRSA carrier to an isolation unit,

staff failed to follow the hospital's infection-control protocol and workers did not thoroughly wash their hands, according to a statement of claim filed in Ontario Superior Court. The claim contains allegations that have not been proven in court.

Bridgepoint Hospital denies causing Mr. Rash's superbug infection, saying none of the patients on his ward tested positive for MRSA during his hospital stay, according to the statement of defence.

» SEE 'SUPERBUGS' PAGE A6

Toronto Globe & Mail, Oct. 2007

Is it possible to control the spread of MRSA?

MRSA Infection Control Strategies



- contact precautions
- screening
- decolonization

Contact Precautions

- Private room or cohort
- Hand hygiene
- Gloves on entering the pt room; remove gloves on exiting
- Gowns for contact with the pt, or the environment
- Limit pt movement out of room
- Dedicate pt care equipment

Contact Precautions Work to Decrease MRSA Transmission

	Source	
	Isolated	Unisolated
Transmissions	5	10
Patient-days	558	72
Rates	0.009	0.140

RR=15.6, 95% CI=5.3-45.6, p<0.0001


Jernigan, Am J Epidemiol 1996

Hosted by Paul Webber paul@webbertraining.com
www.webbertraining.com

The Changing Face of MRSA: Evolving Epidemiology

Dr. Andrew Simor, University of Toronto

A Webber Training Teleclass



Active Surveillance to Control Spread of MRSA

- Active surveillance – finding asymptomatic carriers
- Contact precautions for patients identified as colonized/infected

MRSA Screening Strategies

- high risk patients on admission
- high risk inpatient units (eg. ICU)
- previously known colonized patients or contacts
- periodic point-prevalence surveys
- universal screening

Chromogenic MRSA Media (MRSA-Select)



BD GeneOhm[™] MRSA

Knowing how and when to treat a patient leads to better medicine

Assay Performance

Specificity	99.9%
Sensitivity	99.9%
Negative Predictive Value (NPV)	99.9%
Positive Predictive Value (PPV)	99.9%

In 2006, it was shown that 19% of patients colonized with MRSA at admission develop an infection, and for patients that acquire MRSA within the hospital, 25% go on to develop an infection. Such infections pose up to a 20% mortality risk for these patients.

GeneXpert[®] PCR System - cycled

Click Here

Model: Cepheid[®] PCR System

Price: \$10,000.00

Features: Automated and easy to use, High Throughput, Small footprint, Compact size, On-board thermal cycler, Designed for point-of-care use, Small footprint.

Product Number: BIOCITEC-1.1-PCR

Product Name: Cepheid[®] PCR System

Product Description: The GeneXpert[®] System offers routine pathogen detection (PCR) to small and large labs. The system is the first to fully automate and integrate all the steps required for PCR-based DNA testing: sample preparation, DNA amplification and detection. Designed to simplify the workflow, the system provides a 10-20 minute turn-around time. The GeneXpert[®] System is the only system that provides a single-step, fully automated, and easy-to-use PCR-based DNA testing solution. The GeneXpert[®] System is the only system that provides a single-step, fully automated, and easy-to-use PCR-based DNA testing solution. The GeneXpert[®] System is the only system that provides a single-step, fully automated, and easy-to-use PCR-based DNA testing solution.

Evidence for Effectiveness of Active Surveillance + Contact Precautions


- ecological studies (Verhoef, EJCMIID 1999; Tiemersma, Emerg Infect Dis 2004)
- observational/quasi-experimental studies (Jernigan, Am J Epidemiol 1996; Chaix, JAMA 1999; Huang, Clin Infect Dis 2006; Robicsek, Ann Intern Med 2008)
- mathematical models (Bootsma, PNAS 2006)

Hosted by Paul Webber paul@webbertraining.com
www.webbertraining.com

The Changing Face of MRSA: Evolving Epidemiology

Dr. Andrew Simor, University of Toronto

A Webber Training Teleclass



Universal MRSA Screening

Harbarth, JAMA 2008

- cohort, crossover study, surgical patients, Geneva
- universal screening (PCR) + contact isolation + topical decolonization
- no ↓ nosocomial MRSA transmission
- no ↓ nosocomial MRSA infections

Universal MRSA Screening

Robicsek, Ann Intern Med 2008

- observational cohort study, historic controls, Chicago
- universal screening (PCR) + contact isolation + topical decolonization
- ↓ nosocomial MRSA infections

PCR vs. Chromogenic Media

- prospective, cross-over study, 2 hospital wards, UK
- median time to report MRSA: 47 hrs vs. 21 hrs (culture vs. PCR; $p < 0.001$)
- no reduction in MRSA transmission

Aldeyab, J Hosp Infect 2009

MRSA: The Dutch Experience

- national “search and destroy policy”
 - screening patients, staff
 - strict isolation
 - decolonization
 - environmental cleaning
 - outbreak control

Verhoef, EJCMI 1999; van Trijp, Infect Control Hosp Epidemiol 2007

Controlling MRSA with Broad-Based Infection Control Interventions




Figure 1. Nosocomial infections due to MRSA and all organisms per 1,000 patient days, 2003 through 2007, at VCU Medical Center.

Edmond, Am J Infect Control 2008

Hosted by Paul Webber paul@webbertraining.com
www.webbertraining.com

The Changing Face of MRSA: Evolving Epidemiology

Dr. Andrew Simor, University of Toronto

A Webber Training Teleclass


CA-MRSA Information for Patients and Family Members (1)

- wounds/lesions covered with clean, dry bandages
- frequent hand hygiene, especially after touching infected area/drainage (gloves for dressing changes)
- do not share personal items (towels, washcloths, razors, clothing)

CA-MRSA Information for Patients and Family Members (2)

- wash soiled linens and clothes in hot water and laundry detergent
- avoid contact sports or other skin-to-skin contact until infection has healed
- inform healthcare providers of MRSA

The Hands Give It Away



N Engl J Med 2009

24-YEAR-OLD MAN WHO HAD QUADRIFURCA DUE TO AEROMATIC EPIDENDIUM WAS FOUND ON ROUTINE SURVEILLANCE CULTURES TO HAVE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) COLONIZATION OF HIS ANTERIOR NARES. HE HAD NO HISTORY OF MRSA INFECTION OR COLONIZATION. TO ASSESS THE POTENTIAL IMPLICATIONS OF THE PATIENT'S MRSA CARRIAGE FOR INFECTION CONTROL, AN IMPRINT OF A HEALTH CARE WORKER'S UNGLAVED HAND WAS OBTAINED FOR CULTURE AFTER THE WORKER HAD PERFORMED AN ABDOMINAL EXAMINATION OF THE PATIENT. THE MRSA COLONIES GROWN FROM THIS HANDPRINT ON THE PLATE (STRIBILIGRA) TRAYS, WHICH CONTAINED 1 µg OF CLINDAMYCIN PER MICELLER TO INHIBIT METHICILLIN-RECEPTIVE S. AUREUS, ARE PINK AND SHOW THE OUTLINE OF THE WORKER'S FINGERS AND THUMB (Panel A). WITH THE USE OF A POLYMERASE-CHAIN REACTION ASSAY, THE MRSA GENE, WHICH CONFERS METHICILLIN RESISTANCE, WAS AMPLIFIED FROM SWABS AND IMPRINTS. AFTER THE WORKER'S HANDS HAD BEEN CLEANED WITH ALCOHOL FOAM, ANOTHER HAND IMPRINT WAS OBTAINED, AND THE RESULTING CULTURE WAS NEGATIVE FOR MRSA (Panel B). THESE IMAGES ILLUSTRATE THE CRITICAL IMPORTANCE OF HAND HYGIENE IN Caring FOR PATIENTS, INCLUDING THOSE NOT KNOWN TO CARRY ANTIBIOTIC-RESISTANT PATHOGENS.

Curtis J, Donnelly, M.D., Betsy C. Eckstein, B.S., Cleveland Veterans Affairs Medical Center Cleveland, OH 44168

EVEN CHEETAHS WASH THEIR HANDS...



MRSA - 2009 Summary

- Healthcare-associated MRSA rates and infectious morbidity continue to increase
- Community-associated MRSA has become predominant in many parts of the country
- Controlling spread of MRSA requires active surveillance, attention to hand hygiene, and contact precautions

THE NEXT FEW TELECLASSES	
29 Sep. 09	(Free Teleclass) Voices of CHICA – Part 2 Speaker: CHICA-Canada Board Members & Guests
01 Oct. 09	The Changing Face of MRSA – Evolving Epidemiology Speaker: Dr. Andrew Simor, Sunnybrook Hospital, Toronto
15 Oct. 09	The Socioeconomic Cost of Enteric Disease Speaker: Dr. Doug Scott, CDC
21 Oct. 09	(South Pacific Teleclass) National Work on the Prevention of Healthcare Acquired Infections in Australia Speaker: Dr. Marilyn Cruikshank, Australian Commission on Safety & Quality in Healthcare
22 Oct. 09	(Free Teleclass) Improving Infection Control in Developing Countries Speaker: Dr. Benedetta Allegranzi, World Health Organisation
29 Oct. 09	Prevention of Catheter-Associated Urinary Tract Infection: New
www.webbertraining.com.schedule1.php	

Hosted by Paul Webber paul@webbertraining.com
www.webbertraining.com